NEW YORK (GenomeWeb) – Melbourne, Australia-based Sienna Cancer Diagnostics announced today that it has signed an agreement to acquire US-based Sevident's NET molecular capture platform.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.